Digging into EyePoint Pharma's recent phase 1 data on its anti-VEGF candidate, EYP-1901 in macular edema and wet-AMD

Executed on:Sep 7, 2022 5:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Retina Consultants of Southern CA

Ophthalmologist in private practice & Clinical Faculty at Loma Linda University and the Loma Linda Veterans Affairs Hospital; competed surgical vitreoretinal fellowship at the University of Iowa.
Treats 750 patients with Macular Edema
Specializes in all aspects of vitreoretinal medicine and surgery, as well as uveitis and ocular tumors; has numerous publications in major ophthalmic journals and textbooks.

Interview Goal

A discussion of macular edema and EyePoint pharmaceuticals phase 1 data for its anti-VEGF, EYP-1901. 

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.